company background image
BMRN logo

BioMarin Pharmaceutical NasdaqGS:BMRN Stock Report

Last Price

US$87.34

Market Cap

US$16.7b

7D

3.8%

1Y

-8.3%

Updated

28 Mar, 2024

Data

Company Financials +

BioMarin Pharmaceutical Inc.

NasdaqGS:BMRN Stock Report

Market Cap: US$16.7b

BMRN Stock Overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.

BMRN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance5/6
Financial Health5/6
Dividends0/6

BioMarin Pharmaceutical Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioMarin Pharmaceutical
Historical stock prices
Current Share PriceUS$87.34
52 Week HighUS$100.38
52 Week LowUS$76.02
Beta0.31
1 Month Change-3.68%
3 Month Change-9.42%
1 Year Change-8.34%
3 Year Change12.22%
5 Year Change-5.46%
Change since IPO565.45%

Recent News & Updates

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Feb 29

Recent updates

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Feb 29

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Jan 19

Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Jan 05
Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Dec 15
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Nov 03
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

Aug 09
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

Jul 18
We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 09
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

Apr 18
Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Mar 27
These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

Jan 09
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

BioMarin redesigns organization, will lay off about 4% of its workforce

Oct 07

BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy

Sep 29

BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A

Sep 15

BioMarin to resubmit hemophilia therapy for FDA approval after EU nod

Aug 25

BioMarin may be an activist target after 13-F filings

Aug 15

BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth

Aug 03

BioMarin: More Growth

Jul 21

BioMarin's Solid Pipeline Bears The First Fruit

Jun 27

Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

May 25
Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

BioMarin: A Good Anchor For Your Biotech Portfolio

May 10

BioMarin: Keep Waiting For The Growth

Mar 03

BioMarin Pharmaceutical (NASDAQ:BMRN) Has Debt But No Earnings; Should You Worry?

Feb 24
BioMarin Pharmaceutical (NASDAQ:BMRN) Has Debt But No Earnings; Should You Worry?

BioMarin's Win In Phase 3 Hemophilia Study Makes Its Investment Case Stronger

Jan 11

BioMarin: Voxzogo Approval Could Trigger A Lengthy Bull Run For Cash Rich Biotech

Nov 01

Shareholder Returns

BMRNUS BiotechsUS Market
7D3.8%0.9%0.4%
1Y-8.3%10.3%28.8%

Return vs Industry: BMRN underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: BMRN underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is BMRN's price volatile compared to industry and market?
BMRN volatility
BMRN Average Weekly Movement3.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: BMRN has not had significant price volatility in the past 3 months.

Volatility Over Time: BMRN's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19963,401Alexander Hardyhttps://www.biomarin.com

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.

BioMarin Pharmaceutical Inc. Fundamentals Summary

How do BioMarin Pharmaceutical's earnings and revenue compare to its market cap?
BMRN fundamental statistics
Market capUS$16.72b
Earnings (TTM)US$167.65m
Revenue (TTM)US$2.42b

98.3x

P/E Ratio

6.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BMRN income statement (TTM)
RevenueUS$2.42b
Cost of RevenueUS$1.26b
Gross ProfitUS$1.16b
Other ExpensesUS$989.95m
EarningsUS$167.65m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.89
Gross Margin47.85%
Net Profit Margin6.93%
Debt/Equity Ratio22.0%

How did BMRN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.